MedTrace Logo

A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310

NCT03847207 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-02-19

No results posted yet for this study

Summary

A Phase 1, first in human, three-part, single centre study to assess the safety, tolerability, PK and PD of single ascending subcutaneous doses of HTL0030310 in healthy subjects

Conditions

  • Healthy

Interventions

DRUG

HTL0030310

Solution for Subcutaneous injection

DRUG

Pasireotide

Pasireotide 600 μg for subcutaneous injection

DRUG

Placebo

Matching placebo Solution

Sponsors & Collaborators

  • Nxera Pharma UK Limited

    lead INDUSTRY

Principal Investigators

  • Philip Evans, MBChB · Quotient Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-23
Primary Completion
2020-03-05
Completion
2020-03-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03847207 on ClinicalTrials.gov